2. Mutations of the mRNA are significant. Since COVID-19 is a classic corona virus, being a single stranded mRNA virus, it is known that mutations can be quite frequent. We know that B.1.1.7 is more contagious yet not more virulent. Is this because the spike proteins match the ACE2 receptor better thus initiating multiple virion particles per cell? Also, it has been noted that there are slight ACE2 receptor proteins on Asians as compared to Europeans. If this is the case does this explain for the lower per PoP incidence in China, Korea and Japan?
3. Mutations occur as long as the patients has not developed an immune response. Thus, in immunocompromised patients, including those ill as well as older patients, present a putative clear and present danger as mutation sources. If so, does not this drive the immunization policy as a scientifically based observation?
4. It has been observed that the virus is related to the development of auto-antibodies and thus autoimmune types sequellae. This may affect a broad spectrum of patients. How can this be monitored and in turn treated?
5. Tracking mutations is critical. Is there any proposed plan to establish a genome database for mRNA tracking mRNAs from infected patients? If so, would the primary focus be on changes in the 3,000 nucleotide spike protein or is it necessary to monitor the entire 30,000 nucleotide mRNA? Should such a database be open and accessible? If so, would there be any patient privacy concerns?
Posts
